Publicacións nas que colabora con Rodrigo Jover Martínez (21)

2023

  1. Fecal occult blood and calprotectin testing to prioritize primary care patients for colonoscopy referral: The advantage study

    United European Gastroenterology Journal, Vol. 11, Núm. 7, pp. 692-699

  2. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)

    PLoS Medicine, Vol. 20, Núm. 10

2019

  1. Correction: Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer (Clinical and Translational Gastroenterology, (2019) 10, e-00031, 10.14309/ctg.0000000000000003)

    Clinical and Translational Gastroenterology

  2. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer

    Clinical and translational gastroenterology, Vol. 10, Núm. 1, pp. e00003

2017

  1. Candidate predisposing germline copy number variants in early onset colorectal cancer patients

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 625-632

  2. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs

    United European Gastroenterology Journal, Vol. 5, Núm. 2, pp. 255-260

2015

  1. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer

    Journal of Medical Genetics, Vol. 52, Núm. 7, pp. 498-502

2014

  1. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer

    Human Genetics, Vol. 133, Núm. 5, pp. 525-534

  2. High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families

    Clinical Genetics, Vol. 85, Núm. 6, pp. 583-588

  3. Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests

    Clinical Gastroenterology and Hepatology, Vol. 12, Núm. 10, pp. 1708-1716.e4

2013

  1. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12

    BMC Genomics, Vol. 14, Núm. 1

  2. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern european populations

    Carcinogenesis, Vol. 34, Núm. 2, pp. 314-318

  3. BMPR1A mutations in early-onset colorectal cancer with mismatch repair proficiency

    Clinical Genetics

  4. Corrigendum

    Carcinogenesis

  5. Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

    Pharmacogenomics Journal, Vol. 13, Núm. 3, pp. 209-217

  6. Risk of cancer in cases of suspected lynch syndrome without germline mutation

    Gastroenterology, Vol. 144, Núm. 5

2012

  1. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening

    New England Journal of Medicine, Vol. 366, Núm. 8, pp. 697-706

  2. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer

    Gut, Vol. 61, Núm. 6, pp. 865-872

  3. Seeking genetic susceptibility variants for colorectal cancer: The EPICOLON consortium experience

    Mutagenesis, Vol. 27, Núm. 2, pp. 153-159

2010

  1. Colorectal cancer susceptibility quantitative trait loci in mice as a novel approach to detect low-penetrance variants in humans: A two-stage case-control study

    Cancer Epidemiology Biomarkers and Prevention, Vol. 19, Núm. 2, pp. 619-623